ClinicalTrials.gg
CompletedNCT05552820Updated May 5, 2026

Electroacupuncture for Mild-to-moderate Dry Eye

An interventional study of Verum Electroacupuncture and Sham Electroacupuncture in Dry Eye, sponsored by Shanghai Institute of Acupuncture, Moxibustion and Meridian. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Shanghai Institute of Acupuncture, Moxibustion and Meridian · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
168
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 106 studies in Dry Eye Syndromes with a site in China — 28 open to participants now, 30 under way, 3 of them phase 3. Dry Eye Syndromes · China.

Enrollment
20th of 83
168 · median 80
Started
2023
with 15 others
No phase
46 of 106
10 open now
Registered
48th of 106
by date

Among the 106 studies in Dry Eye Syndromes with a site in China, this one is the 20th largest by enrollment of the 83 interventional ones that give a count, is one of 16 that started in 2023, is one of 46 with no phase, and was the 48th registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

28 of the 106 studies in Dry Eye Syndromes with a site in China are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Dry Eye Syndromes with a site in China, or all of them as a file.
02

Study summary

To determine if electroacupuncture acts as an dry eye treatment rather than a placebo, and identify if benefits are linked to corneal subbasal nerve changes and neuroimmunomodulatory indicators.

Read the detailed description

Acupuncture is an important method in the treatment of diseases in Chinese medicine and plays an important role in the treatment of many diseases. Electroacupuncture (EA), as a combination of acupuncture and electric stimulation, is now widely used in research and clinical treatment. Our preliminary study found that compared with 0.1% sodium hyaluronate eye drops, EA exerted more beneficial and durable effects after four weeks of treatment. However, the placebo effect of EA cannot be ruled out yet. The aim of this study is to determine if EA acts as an dry eye treatment rather than a placebo, and identify if benefits are linked to corneal subbasal nerve changes.

This is a multicenter, randomized, subject-blinded, sham-controlled trial. A total of 168 participants with mild-to-moderate dry eye will be randomly assigned (1:1) to verum EA or non-penetrating non-acupoint sham EA (3 times weekly for 4 weeks), followed by a 24-week follow-up. The primary efficacy outcome is the change from baseline to week 4 in the Noninvasive Tear Breakup Time (NIBUT). Secondary efficacy outcomes include tear meniscus height (TMH), Schirmer I test (SⅠT), corneal topography, corneal and conjunctival sensation, scores of Ocular Surface Disease Index (OSDI), corneal fluorescein staining (CFS), Numerical rating scale (NRS), and Chinese Dry Eye Related Quality of Life Scale (CDERQOL) . Additionally, we will apply the Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder (GAD-7) to understand the mental health conditions of patients. IVCM will be performed to observe the morphological changes of the corneal basal nerve. The changes of NGF, CGRP, NPY, 8-OHDG, 4-HNE, MDA and other neuroimmunomodulatory indicators in tears and conjunctival cells will be detected by immunofluorescence, ELISA, or other techniques.

03

Conditions studied

  • Dry Eye

Browse trials for

Keywords

  • Dry eye
  • Electroacupuncture
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients meeting the diagnostic criteria for dry eye according to the TFOS DEWS Ⅱ
  • Ages 18-65 years, no gender limit

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with severe dry eye
  • Combined with other eye diseases (e.g. severe blepharitis, blepharospasm, conjunctival laxity, strabismus, amblyopia, glaucoma, cataract, fundus disease, ocular trauma)
  • With active eye diseases or a history of eye surgery within 3 months
  • Received acupuncture treatment or other dry eye treatment measures within 1 month that may influence the assessment of efficacy
  • Previously experienced electroacupuncture intervention
  • Pregnant or breastfeeding females
  • Serious systemic diseases such as cardiovascular, cerebrovascular, hepatic, renal, and hematopoietic system and psychiatric disorders
  • With diseases such as Sjögren's syndrome, rheumatoid arthritis, systemic lupus erythematosus, or ankylosing spondylitis
  • With damaged, ulcerated, infected, or scarred skin at the selected acupoints
  • Allergic to metal or tape
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
168 participants (actual)

Study arms

  • Experimental
    Verum Electroacupuncture

    Verum electroacupuncture treatment will be given 3 times a week, at least 1 day apart , for consecutive 4 weeks with a 24-week follow-up. Each session lasts for 30 min.

    Device: Verum Electroacupuncture

  • Sham comparator
    Sham Electroacupuncture

    Sham electroacupuncture on non-acupoints plus non-penetrating plus no electrical stimulation will be given 3 times a week, at least 1 day apart , for consecutive 4 weeks with a 24-week follow-up. Each session lasts for 30 min.

    Device: Sham Electroacupuncture

Interventions

  • DeviceVerum Electroacupuncture

    Acupoints: Cuanzhu (BL2), Taiyang (EX-HN5), Sibai (ST1), Sizhukong (TE23), Baihui (GV20), Fengchi (GB20), Hegu (LI4), Zusanli (ST36), Guangming (GB23), Sanyinjiao (SP6), and Taichong (LR3). All acupoints will be taken bilaterally, except Baihui (GV20). The subject is placed in the supine position with eyes close. After routine sterilization, the sterile polyethylene cylindrical needle pad will be adhered to the acupoints. Then, the sterile acupuncture needles (0.25 mm×0.40 mm, Hwato brand, China.) will be inserted into the skin through the needle pad. Twirling and lifting-thrusting manipulations will be performed on the acupoints until Deqi is reported by the subject. Two pairs of electrodes will be connected at the needle handles on BL2 and EX-HN5 with a 2 Hz, continuous-wave electro-stimulation provided by the electroacupuncture apparatus (SDZ-Ⅲ type, Hwato brand, China). The pulse amplitude is about 1-2 mA.

  • DeviceSham Electroacupuncture

    Sham acupoints: SA1(1 cm above BL2), SA2 (1 cm above SJ23),SA3 (1 cm above EX-HN5), SA4 (1 cm lateral to ST2), SA5 (the midpoint of the line between GV20 and right EX-HN1), SA6 (the midpoint of the line between GB20 and SJ16), SA7 (1 cm lateral to LI4), SA8 (the midpoint of the line between ST36 and GB34), SA9 (the midpoint of the line between GB37 and BL58), SA10 (1 cm backward to SP6), SA11 (the midpoint of the line between LR3 and SP4). After routine sterilization, placebo needles will be used (Streitberger, Asia-med GmbH). The tingling sensation produced when the Streitberger needle is fixed on the skin causes the subject to believe that the needle is piercing the skin, simulating a skin puncture. The electric stimulator is applied to bilateral SA1 and SA3 with no current output. The exterior appearance, indicator light, prompt tone of the sham device, and stimulation parameters are all indistinguishable from the normal one.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Noninvasive Tear Breakup Time (NIBUT)

    The interval between a complete blink and the first breakup of tear film (indicated by a break or deformed Placido disc image on the screen) will be recorded. The measurements are carried out 3 times and the average value is considered as NIBUT.

    Time frame: Baseline, Week 4, Week 8, Week 16, Week 28

Secondary outcomes

  1. Change From Baseline in Tear Meniscus Height (TMH)

    The digital slit lamp (SL990N, CSO, Italy) is applied to take images of the tear meniscus at the lower lid margin in a dark room. The tear meniscus height directly below the central pupil is measured with the system's built-in caliper tool.

    Time frame: Baseline, Week 4, Week 8, Week 16, Week 28

  2. Change From Baseline in Ocular Surface Disease Index (OSDI)

    The OSDI scale is used to assess subjective symptoms related to dry eye, including ocular symptoms, visual function and environmental triggers, with a total score ranging from 0 to 100. The higher the score, the more severe the subjective symptoms.

    Time frame: Baseline, Week 4, Week 8, Week 16, Week 28

  3. Change From Baseline in Corneal Fluorescein Staining (CFS)

    Sodium fluorescein ophthalmic strips (Tianjin Jingming New Technology Development Co., Ltd., China) are used to evaluate corneal epithelial damage. According to the Oxford grading scheme, the CFS score ranges from 0 (no damage) to 5 (severe damage).

    Time frame: Baseline, Week 4, Week 8, Week 16, Week 28

  4. Change From Baseline in Corneal Topography

    The corneal topography system is used to take photographs. The subjects are asked to blink naturally 3 to 4 times, and after the last full blink, they look at the central light source of the Placido disk for 10 s. The researchers take photographs of the anterior corneal surface immediately after the blink and at 10 s of continuous gaze. The SRI and SAI are systematically analyzed and obtained at 10 s.

    Time frame: Baseline, Week 4, Week 8, Week 16, Week 28

  5. Change From Baseline in Corneal and Conjunctival sensation

    The Cochet-Bonnet perception meter (Luneau Chartres, France) will be used to evaluate the corneal perception (including central, superior, inferior, nasal, and temporal corneas, all 2 mm from the corneal rim) and conjunctival perception (including temporal and nasal bulbar conjunctivae, both 3 mm from the corneal rim; superior and inferior conjunctiva, at the center of the eyelid). The measured fiber length will be converted to g/mm2 according to the criteria provided by the supplier, with a higher threshold indicating a more insensitive perception.

    Time frame: Baseline, Week 4, Week 8, Week 16, Week 28

  6. Change From Baseline in Schirmer I test (SⅠT)

    SⅠT will be performed using a tear detection filter strip (Tianjin Jingming New Technology Development Co., Ltd., China). Patients are requested to avoid eye movement. The strips will be removed after 5 min, and recorded the wetting length.

    Time frame: Baseline, Week 4, Week 8, Week 16, Week 28

  7. Change From Baseline in Numerical Rating Scale (NRS)

    Subjects are asked to rate their current Iocular pain intensity in the right and left eye (0-10 numerical rating scale, NRS) followed by placement of 0.4% hydroxybuprocaine hydrochloride (Santen Pharmaceutical Co., LTD., Japan), and rerating of pain 30 seconds later.

    Time frame: Baseline, Week 4, Week 8, Week 16, Week 28

  8. Change From Baseline in Chinese Dry Eye Related Quality of Life Scale (CDERQOL)

    CDERQOL includes 5 domians containing 45 items rated on a 5-point Likert scale ranging from 1 (completely disagree) to 5 (completely agree).

    Time frame: Baseline, Week 4, Week 8, Week 16, Week 28

  9. Adverse events

    Any adverse events will be recorded. EA-related adverse events include local bleeding, subcutaneous hematoma, pain, itch, infection, and generalized symptoms such as dizziness and palpitation during treatment.

    Time frame: Week 4

Other outcomes

  1. Change From Baseline in Generalized Anxiety Disorder (GAD-7)

    The scale consists of 7 items with 4 frequency options for each question, ranging from "not at all (0)" to "almost every day (3)", with the following criteria: no anxiety (0-4); mild anxiety (5-9); moderate anxiety (10-14); and severe anxiety (15-21). 14 points); and severe anxiety (15-21 points).

    Time frame: Baseline, Week 4, Week 8, Week 16, Week 28

  2. Change From Baseline in Patient Health Questionnaire-9 (PHQ-9)

    The scale consists of 9 items with 4 frequency options for each question, ranging from "not at all (0)" to "almost every day (3)", with the following criteria: no depression (0-4); mild depression (5-9); moderate depression (10-14); moderate to severe depression (15-19); and severe depression (20-27). 14 points); moderate to severe depression (15-19 points); and severe depression (20-27 points)

    Time frame: Baseline, Week 4, Week 8, Week 16, Week 28

  3. Change in morphological changes of the corneal basal nerve

    In vivo confocal microscopy (IVCM) is performed to initially observe the morphological changes of the corneal basal nerve. IVCM images are taken with a Heidel-berg Retina Tomograph III (HRT III; Heidelberg Engi¬neering, Germany). The ACCMetrics analysis software (M.A. Dabbah, lmaging Science Biomedical Engineering, Manchester, UK) is used to calculate nerve morphological parameters for the selected images.

    Time frame: Baseline, Week 4

  4. Change in neuroimmunomodulatory indicators in tears and conjunctival cells

    Schirmer test strip is s used to collect tears from patients before and after treatment. Conjunctival impression cytology is used to obtain conjunctival cells. Immunofluorescence, ELISA and other techniques are used to detect the changes in NGF, CGRP, NPY, 8-OHDG, 4-HNE, MDA and other neuroimmunomodulatory indicators in tears and conjunctival cells of subjects.

    Time frame: Baseline, Week 4

07

Study locations

1 site
  • Guang Yang
    Shanghai, 20030, China
08

References and documents

Publications

  • Lu YQ, Yang G, Li MY, Hong J, Yang YT, Wang XJ, Kong XH, Zhao Y, Ma Z, Huang XY, Zou YL, Zhou XT, Ma XP. Electroacupuncture for mild-to-moderate dry eye: study protocol for a multicentre, randomised, single-blind, sham-controlled trial. BMJ Open. 2023 Dec 6;13(12):e069369. doi: 10.1136/bmjopen-2022-069369. PubMed 38056935 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2023 to primary completion in Oct 2025, 22 months.

Of 200 non-industry interventional studies with no phase under Dry Eye Syndromes, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 25. This study's 22 months is above that.

Counting every sponsor, half of 315 studies reached it within 10 months; a quarter within 4 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2022
First posted
Sep 23, 2022
StartActual
Dec 12, 2023
Primary completionActual
Oct 18, 2025
CompletionActual
Apr 20, 2026
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05552820
Lead sponsor
Shanghai Institute of Acupuncture, Moxibustion and Meridian
Collaborators
Shanghai Eye Disease Prevention and Treatment Center, Eye & ENT Hospital of Fudan University
Responsible party
Sponsor
First posted
Sep 23, 2022
Start date
Dec 12, 2023
Primary completion
Oct 18, 2025
Completion
Apr 20, 2026
Last update
May 5, 2026

Study contacts

Xiaopeng Ma, MD, PhD
study chair · Shanghai University of Traditional Chinese Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion